National Pension Service Buys 9,816 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

National Pension Service grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 555,442 shares of the medical equipment provider's stock after acquiring an additional 9,816 shares during the period. National Pension Service owned 0.16% of Intuitive Surgical worth $187,384,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider's stock worth $8,730,184,000 after acquiring an additional 196,316 shares during the last quarter. Jennison Associates LLC raised its position in Intuitive Surgical by 6.4% during the third quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider's stock valued at $1,340,205,000 after purchasing an additional 274,692 shares in the last quarter. Fisher Asset Management LLC raised its position in Intuitive Surgical by 2.0% during the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider's stock valued at $1,516,222,000 after purchasing an additional 88,977 shares in the last quarter. Invesco Ltd. raised its position in Intuitive Surgical by 6.6% during the third quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider's stock valued at $1,096,231,000 after purchasing an additional 232,205 shares in the last quarter. Finally, Northern Trust Corp raised its position in Intuitive Surgical by 3.4% during the third quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider's stock valued at $1,027,230,000 after purchasing an additional 115,059 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded up $5.08 during trading on Thursday, hitting $385.45. 882,172 shares of the company traded hands, compared to its average volume of 1,594,653. The business's fifty day moving average is $385.21 and its 200 day moving average is $352.17. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The firm has a market capitalization of $136.72 billion, a price-to-earnings ratio of 69.58, a P/E/G ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the business earned $1.00 earnings per share. The business's quarterly revenue was up 11.5% compared to the same quarter last year. On average, analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ISRG. Truist Financial boosted their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, January 24th. StockNews.com cut shares of Intuitive Surgical from a "buy" rating to a "hold" rating in a research note on Thursday, February 29th. Barclays boosted their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an "overweight" rating in a research note on Thursday, January 25th. Piper Sandler boosted their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an "overweight" rating in a research note on Friday, April 19th. Finally, Raymond James boosted their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an "outperform" rating in a research note on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and a consensus price target of $396.17.

Insider Activity

In other news, Director Alan J. Levy sold 2,000 shares of the company's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of the company's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 196 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 147,927 shares of company stock worth $57,064,459. Company insiders own 0.80% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.